Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study

Allergy ◽  
2017 ◽  
Vol 73 (1) ◽  
pp. 221-229 ◽  
Author(s):  
C.-y. Lin ◽  
C.-W. Wang ◽  
C.-Y. R. Hui ◽  
Y.-C. Chang ◽  
C.-H. Yang ◽  
...  
2021 ◽  
Vol 12 ◽  
Author(s):  
Peter J. Eggenhuizen ◽  
Boaz H. Ng ◽  
Janet Chang ◽  
Ashleigh L. Fell ◽  
Rachel M. Y. Cheong ◽  
...  

Epidemiological studies and clinical trials suggest Bacillus Calmette-Guérin (BCG) vaccine has protective effects against coronavirus disease 2019 (COVID-19). There are now over 30 clinical trials evaluating if BCG vaccination can prevent or reduce the severity of COVID-19. However, the mechanism by which BCG vaccination can induce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell responses is unknown. Here, we identify 8 novel BCG-derived peptides with significant sequence homology to either SARS-CoV-2 NSP3 or NSP13-derived peptides. Using an in vitro co-culture system, we show that human CD4+ and CD8+ T cells primed with a BCG-derived peptide developed enhanced reactivity to its corresponding homologous SARS-CoV-2-derived peptide. As expected, HLA differences between individuals meant that not all persons developed immunogenic responses to all 8 BCG-derived peptides. Nevertheless, all of the 20 individuals that were primed with BCG-derived peptides developed enhanced T cell reactivity to at least 7 of 8 SARS-CoV-2-derived peptides. These findings provide an in vitro mechanism that may account, in part, for the epidemiologic observation that BCG vaccination confers some protection from COVID-19.


2002 ◽  
Vol 11 (4) ◽  
pp. 669-674 ◽  
Author(s):  
S. Carlens ◽  
D. Liu ◽  
O. Ringdén ◽  
J. Aschan ◽  
B. Christensson ◽  
...  

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4543-4543 ◽  
Author(s):  
T. Buanes ◽  
S. Bernhardt ◽  
K. Lislerud ◽  
I. Gladhaug ◽  
M. Moeller ◽  
...  

4543 Background: K-RAS mutations are found in most adenocarcinoma of the pancreas, and targeting mutant RAS by vaccination may be of clinical importance. The present follow-up study was performed to determine whether or not mutant RAS specific T cells were still present in long term survivors seven to nine years after postoperative adjuvant vaccination with synthetic mutant RAS peptides Methods: During 1995–98, all together 23 patients were recruited into two clinical studies. The patients in CTN95002 (n = 10) were given a single mutant RAS peptide (100μg) corresponding to the RAS mutation identified in the patient’s tumor. Patients in CTN98010 (n = 13) were given a mixture of seven mutant RAS peptides, (700μg), corresponding to the most common mutations in pancreatic adenocarcinoma, in a 10 week vaccination regimen, using GM-CSF as an adjuvant, and boosters for an extended period. Immune responses were measured as skin reaction (DTH) and/or in vitro T-cell response. Blood samples from the five patients, still alive in 2006, were investigated by in vitro T-cell proliferation assay for immunological memory. Results: The five surviving patients were all immune responders during the primary vaccination period. Analysis of T-cell reactivity was performed seven (one patient), eight (one patient) and nine years (three patients) after resection/vaccination. Three patients still showed immune responses against the vaccine given previously. T cell reactivity against the Gly12Val mutation was observed in one patient receiving this peptide. In another patient a strong T cell reactivity against all seven peptides present in the vaccine, was observed. Conclusions: Long term survival beyond seven to nine years was only found in patients who primarily responded immunologically on the RAS-vaccination. Long term immunological memory can be induced by peptide vaccination. No significant financial relationships to disclose.


Author(s):  
Olga F. Belaia ◽  
S. A. Potekaeva ◽  
E. V. Volchkova ◽  
O. A. Payevskaya ◽  
S. N. Zuevskaya ◽  
...  

Erysipelas is a widespread infectious disease, with severe hemorrhagic forms, frequent recurrence and complications. Activation of T-cell immunity by individual streptococcus antigens determines the nature of the course and outcomes of erysipelas. Laser therapy is widely used in the treatment of erysipelas, however, indications for its purpose are often empirical, laboratory criteria for indications for purpose are absent. The goal is to study the effectiveness of infrared laser therapy in terms of the dynamics of leukocyte migration in vitro in response to S. pyogenes antigens. Materials and methods. 95 patients with erysipelas (55 women and 40 men) aged 20-65 years were examined, of which 34 were with primary erysipelas of extremity, 23 were with face erysipelas, 39 were with relapsed l erysipelas of extremity. All patients received basic antibiotic therapy. Laser therapy of the local focus area was performed in 30 of them. The leukocyte migration is determined in vitro by screening test of cell migration (STCM) during stimulation with polysaccharide, surface proteins, and the antigen of L-forms of S. pyogenes in various concentrations. Results. Laser therapy of patients with erysipelas had a noticeable immunomodulatory effect in the reaction of blood cells to the polysaccharide and surface proteins. At the same time, in patients with erythematous-hemorrhagic form of erysipelas, the clinical effect was manifested in a shorter duration of erythema, edema, hemorrhages, and regional lymphadenitis. Conclusion. The STCM method, which makes it possible to evaluate the migration of leukocytes to the surface specific antigens of streptococcus, can be used as a screening method for patients with erysipelas, in whom laser therapy may have a more pronounced effect.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 1173-1173
Author(s):  
Nora Mirza ◽  
Manfred Zierhut ◽  
Andreas Korn ◽  
Antje Bornemann ◽  
Christoph Simon ◽  
...  

Abstract Graft versus Host Disease (GvHD) is the major complication of allogeneic hematopoetic cell transplantation (HCT). It mostly affects the gastrointestinal tract, skin or liver, but may also involve the central nervous system (CNS). Although GvHD is believed to be mainly mediated by T cells recognizing HLA mismatches or minor histocompatibility antigens (MHC-restricted peptides differing in single amino acids based on protein sequence variants between donor and recipient due to genetic differences), limited evidence is known about the exact MHC-restricted T cell epitopes recognized on recipient cells. In this study, we evaluated the clinical manifestation of GvHD in the posterior eye segment (PS) as part of the CNS and characterized self-antigens mediating reactivity of allogeneic T cells. The first patient group comprised 6 individuals (3 women and 3 men, median age 40 years, range 20-58 years) with diseases of the PS after HCT. Diseases were ALL (n=4), AML (n=1) and MPS (n=1). 8 transplantations (1-2 per patient) were performed using grafts from matched related (MRD, n=1), matched unrelated (MUD, n=4), mismatched unrelated (MMUD, n=2) or haploidentical (n=1) donors. The second group included 22 patients (7 women and 15 men, median age 55 years, range 29-69 years) irrespective of ocular symptoms recruited before HCT. Diseases were AML (n=7), CML (n=1), MDS (n=4), MPS (n=5), multiple myeloma (n=1) and lymphoma (n=4). All patients received grafts from HLA-identical donors (MRD n=7, MUD n=15). GvHD prophylaxis was performed using standard protocols. Peripheral blood mononuclear cells (PBMC) and DNA were isolated from blood samples. Autologous cell samples were blood samples before or oral mucosa after HCT. Allogeneic cells were obtained from patients with complete donor chimerism. DNA sequencing was performed to identify donor-recipient single nucleotide polymorphisms (SNP). Retina specific candidate epitopes derived from the retinal guanylate cyclase 2D (GUCY2D), the retinoid binding protein (RBP) and the guanylate cyclase activating proteins A1 und B1 (GUCA1A/GUCA1B) were predicted based on known SNP and individual protein sequences using the database EpiToolKit. PBMC were prestimulated with both wildtype and SNP peptides. T cell reactivity was determined in ELISpot and intracellular cytokine staining. Moreover, T cells from 5 family donors were evaluated. All epitopes were evaluated in at least 8 healthy individuals carrying the respective HLA-subtype. Immunogenicity of MHC-I restricted candidate epitopes was determined in in vitro priming. PS diagnoses were optical atrophy (n=2), in 1 case combined with a selective dysfunction of the cones, optic neuritis (n=2), anemic retinopathy (n=1) and VZV retinitis (n=1). In two of these patients (one with selective cone dystrophy, the other with VZV retinitis) antigen specific T cells against MHC-II restricted GUCY2D epitopes could be detected 24 and 40 months after HCT. DNA sequencing did not reveal a SNP indicating recognition of self-antigens. In 6/22 patients without PS symptoms, retina-specific T cells could be detected, here directed against MHC-II restricted epitopes derived from GUCA1A (n=3), GUCA1B (n=3) and GUCY2D (n=3) between 4 and 14 months after HCT. After stimulation with the variant peptide, no T cell reactivity occurred, confirming that the observed responses were sequence specific. T cell responses tended to increase over time but could disappear at certain time points. Again, no SNP could be observed. Hence, T cell reactivity was directed against self-epitopes. Transplantation of retina-antigen specific cells and cross-reactivity against naturally occurring epitopes were excluded since no reactivity could be detected in donor samples and healthy individuals. In in vitro priming experiments, 36/55 of MHC-I restricted peptides could be confirmed as T cell epitopes. Thus, GvHD manifestations of the retina can be detected in patients after allogeneic HCT and can be mediated by antigen-specific T cells. Development of PS GvHD may be triggered by viral infections and should be considered in case of atypical ophthalmologic findings. The antigens recognized hereby can be self-antigens and do not need to be based on genetic differences between donor and recipient. In summary, recognition of self-antigens by allogeneic T cells represents a novel pathomechanism of graft-host-interaction in patients undergoing allogeneic HCT. Disclosures No relevant conflicts of interest to declare.


1978 ◽  
Vol 148 (5) ◽  
pp. 1414-1422 ◽  
Author(s):  
SJ Burakoff ◽  
R Finberg ◽  
L Glimcher ◽  
F Lemonnier ◽  
B Benacerraf ◽  
...  

We have analyzed the cellular basis of T-cell reactivity against lymphocytes expressing major histocompatibility complex (MHC) products that are foreign by virtue of polymorphism (alloantigens) or because of modification by chemicals or viruses. We find that early in ontogeny, prekiller activity against both trinitrophenyl (TNP)-coupled autologous MHC products and allogeneic MHC products resides in the same (Ly123(+)) T-cell pool; later in ontogeny alloreactivity is invested in Ly23 cells which, when activated, lyse TNP-coupled autologous cells as well as appropriate allogeneic target cells. We demonstrate that stimulation of Ly123(+) T cells in vitro by autologous cells coated with chemically-inactivated Sendai virus results in the formation of Ly23(+) cytolytic T lymphocytes (CTL) that specifically lyse both virus modified autologous target cells and unmodified allogeneic target cells. These results suggest the following model to account for the presence of large numbers of alloreactive T-cell clones in adult animals: continuous stimulation of Ly123 cells by autologous MHC antigens associated with foreign materials such as a virus results in the formation of Ly23 memory progeny carrying receptors that recognize MHC products that are foreign due to genetic polymorphism (alloantigens). In general, these studies indicate that alloaggression (as manifest by Ly23 cells in the CTL response) reflects a high degree of cross stimulation between physiologically relevant antigens, e.g., viral determinants associated with self MHC products, and biologically irrelevant allelic variants of the MHC.


1995 ◽  
Vol 89 (s33) ◽  
pp. 14P-14P
Author(s):  
M Hawa ◽  
T Lohmann ◽  
M Londei ◽  
D Leslie

2013 ◽  
Vol 58 ◽  
pp. S143-S144
Author(s):  
J.R. Larrubia ◽  
M.U. Lokhande ◽  
S. García-Garzón ◽  
J. Miquel ◽  
A. González-Praetorious ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document